ABL1 and acute lymphoblastic leukemia: Although there is no direct evidence to support INPP5D-ALK as a driver mutation, it is worth considering that INPP5D-ABL1 fusion has exhibited sensitivity to imatinib in a patient with acute lymphoblastic leukemia [24].